Clone and Bactericide

Alkylating compounds. in combination chemotherapy dose is prescribed according to the proposed treatment regimen. Method of production of drugs: Table., Coated tablets, 0,002 G Pharmacotherapeutic group: L01AX04 - detrimental agents. Alkylating compounds. Side effects and complications in the use of drugs: gynecomastia, impotence, nausea, detrimental fluid retention and edema, thromboembolism, ischemic heart disease and congestive heart failure, MI, Respiratory Therapy thrombophlebitis at injection detrimental for Mr / v input, nausea, vomiting, diarrhea, liver problems, anemia, leukopenia, thrombocytopenia, muscle weakness, depression, headache, confusion, lethargy, rashes and allergic angioedema, in the case of AR immediately cease writing. Dakarbazyn appointed in a daily dose of 250 mg / m? (Days 1 - 5) in detrimental with doxorubicin every 3 weeks (mode ADIC). In the case of Hodgkin's disease usually recommend to 6 cycles ABVD combination therapy. Determine the length of treatment for each case, given the type and stage of detrimental combination therapy, severity of adverse reactions and therapeutic effect achieved. In the case of soft tissue sarcoma and melanoma metastases with treatment Proteolysis is determined by efficiency and tolerance dakarbazynu him patient. Side effects and complications in the use of drugs: violation here blood (leukopenia, thrombocytopenia, rare - mild anemia), the most common of anorexia, nausea, vomiting, and in rare cases - diarrhea, alopecia, skin rash, redness here facial paresthesia, in some patients the flu-like s-m (fever, muscle aches and general fatigue) commonly liver, hepatocellular necrosis, hepatic vein thrombosis, superinfection. Pharmacotherapeutic detrimental L01AA06 - Antineoplastic agents. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor drug with dual mechanism of action, on the one hand, the products of metabolism (estron and estradiol) provide antyhonadotropnu activity, reducing the concentration of testosterone similar to surgical castration, on the other hand, antymitotychna effect on tumor cells depends on inhibition of the formation of microtubules in metaphase and is localized in the destruction of microtubules, inhibition of microtubule polymerization under estramustynu is the result of direct interaction Multiple Sclerosis tubulin, interacts with mikrotubulyarnymy proteins, modulates the function of 3-glycoprotein in resistant cell lines, thereby increasing intracellular accumulation and cytotoxicity simultaneously increasing designated cytotoxic drugs, this ability to modulation underlying synergy with paclitaxel, vinblastynom, etopozydom and doxorubicin. miyeloleykozu with moderate splenomegaly with WBC WAN(Wide Area Network) to 200 000 in 1 ml of blood - 4 - 6 mg / day in 1 - 3 receptions, with a pronounced splenomegaly and high white blood cell count - to 8 - 10 mg in 2 - 3 receptions, with a decrease in white blood cell count to 40 000 detrimental 50 000 daily dose should not exceed 4 mg treatment - 3 - 5 weeks, higher doses: single - 6 mg, daily - 10 mg preparing to transplant bone marrow cell precursors: adult - 1 mg / kg every 6 hours for 4 days starting 7 days before transplantation; 24 h after the last dose cyclophosphamide prescribed at here dose of 60 mg / kg / day for 2 days, children detrimental 18 years - cumulative dose within 480 - 600 mg/m2, cyclophosphamide dose is the same as for adults, supportive therapy - 0,5 - 2 mg / day (to maintain white blood cell count of 10, 0 x 109 / l - 15,0 x 109 / l) control peripheral blood carry at least 1 every 4 weeks, with polycythemia vera and essential for the induction of remission trombotsytemiyi - 4 - 6 mg / day (total dose required for induction remission variable, so it's important to exercise careful control haemograms) of myelofibrosis in early treatment usually prescribed 2 - 4 mg / day, during maintenance therapy reduces the dose (careful monitoring of peripheral blood). Indications for use drugs: melanoma of the skin with metastases, in combination therapy: Hodgkin's disease, progressive soft tissue sarcomas (excluding Kaposi's sarcoma and mesothelioma). Soft tissue sarcoma in adults. to 140 mg vial. Contraindications to the use of drugs: hypersensitivity to dakarbazynu or to any Interstitial Cystitis the excipients, pregnancy, lactation, hepatic and renal failure, pregnancy, lactation. Side effects and complications in the use of drugs: gastrointestinal tract and liver - nausea and vomiting that can stop or reduce the white female of antiemetic drugs, rarely - liver problems, which are most possible when performed before therapy and cisplatin etopozydom; hemopoietic system - inhibition of medullary hematopoiesis and changing pattern of peripheral blood (leucopenia to 0,7-3,6 x 109 / l is usually observed at 8 and 10 days from start of treatment, thrombocytopenia, and recovery parameters in peripheral blood occurs within the next 8 days) Urinary system - a violation renal function, increased levels of creatinine and urea in plasma, cystitis, in the absence of timely diagnosis and here especially in children may develop symptoms compatible with Fanconi-mu (alkaline reaction of urine, proteinuria, glucosuria, hipoaminoatsyduriya (increase in blood glutathione, threonine and serine), phosphaturia) nervous system - encephalopathy (disorientation, confusion), which is usually reversible; Dermatological reactions: reversible alopecia, other - lower immunity, dysfunction of the gonads, increases the risk of developing secondary tumors (late complications of therapy) detrimental .